Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
30 hedge funds and large institutions have $6.46M invested in Biora Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 19 closing their positions.
782% more call options, than puts
Call options by funds: $3.24M | Put options by funds: $367K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $8.72M → $6.46M (-$2.26M)
29% less funds holding
Funds holding: 42 → 30 (-12)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$144K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$71.2K |
| 3 |
LPL Financial
San Diego,
California
|
+$67.1K |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$55.6K |
| 5 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$51.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.1M |
| 2 |
Millennium Management
New York
|
-$209K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$88.4K |
| 4 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
-$32.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$17.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$3 | – | – |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$68 | +2 | New |
|
BIOR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q1 2023, worth a combined $6.46M — down 26% from $8.72M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of BIOR and 7 opened new positions — a net loss of 12 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $144K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.1M sold.
- 30 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q1 2023, down from 42 in Q4 2022.
- Funds reported $6.46M of Biora Therapeutics, Inc. Common Stock stock for Q1 2023, down 26% quarter-over-quarter.
- 7 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q1 2023 and 19 closed out, a net change of -12 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q1 2023 was Schonfeld Strategic Advisors, an estimated $144K added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2023.